Who is eligible for clinical trial NCT05536804?

Participants must meet the protocol's inclusion criteria for Overweight. The stated age range is 18 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT05536804 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-05-06

A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes (NCT05536804)

Tirzepatide Study of Renal Function in People With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes: Focus on Kidney Hypoxia in Relation to Fatty Kidney Disease Using Multiparametric Magnetic Resonance Imaging

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Eli Lilly and Company

🩺 Plain-English Summary (8th-Grade Level)

We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D). The study will last about 56 weeks and include up to 12 visits.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (8 items) and avoid the listed exclusions (10 items).

Location: Valley Clinical Trials, Inc. — Northridge, California

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

All participants with or without diabetes:
Have a Body Mass Index (BMI) ≥27 kilogram/square meter (kg/m²) at screening
Diagnosed with chronic kidney disease (CKD)
Has an estimated glomerular filtration rate (eGFR) ≥25 to ≤60 ml/min/1.73 m² or eGFR ≥25 to ≤75 ml/min/1.73 m² if urine albumin-to-creatinine ratio (UACR) \>30 milligram/gram (mg/g)
Have been receiving an angiotensin-converting enzyme (ACE) or angiotensin II receptor blockers (ARB) that is considered the maximal appropriate dose by the investigator for treatment of chronic kidney disease or hypertension (unless the participant has low blood pressure or hypotension) Participants without diabetes:
Have Hemoglobin A1c (HbA1c) \<6.5% at screening Participants with Type 2 diabetes:
Have been diagnosed at least 180 days prior to screening
Have HbA1c ≤9.5% at screening

Usually NOT eligible if any of the following apply:

Exclusion Criteria: All participants:
Have a self-reported change in body weight \>5 kilogram (kg) within 90 days prior to screening.
Have a prior or planned surgical treatment for obesity
Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 180 days
Have eGFR \<25 mL/min/1.73m² calculated by using creatinine-based chronic kidney disease epidemiology collaboration (CKD-EPI) equations, as determined by central laboratory at screening.
Have a history of unstable or rapidly progressing renal disease according to investigator judgment
Have a known clinically significant gastric emptying abnormality (for example, severe diabetic gastroparesis or gastric outlet obstruction) or chronically take drugs that directly affect GI motility)
Have had a history of chronic or acute pancreatitis Participants with T2D:
Have history of proliferative diabetic retinopathy or diabetic macular edema or non-proliferative diabetic retinopathy that requires acute treatment.
Have been diagnosed with type 1 diabetes (T1D) or have history of ketoacidosis or hyperosmolar state/coma

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (27 Sites)

Showing the first 25 of 27 sites.

Valley Clinical Trials, Inc. — Northridge, California
University of Colorado Anschutz Medical Campus — Aurora, Colorado
Kidney Associates of Colorado — Denver, Colorado
American Health Network of Indiana, LLC - Avon — Avon, Indiana
American Health Network of Indiana, LLC - Greenfield — Greenfield, Indiana
Indiana University Health University Hospital — Indianapolis, Indiana
American Health Network of Indiana, LLC - Muncie — Muncie, Indiana
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division — Troy, Michigan
University of Washington Medical Center - Montlake — Seattle, Washington
Providence Medical Research Center - Spokane — Spokane, Washington
Klinik Landstraße — Vienna,
Zentrum für klinische Studien Dr Hanusch Gmbh — Vienna,
Klinik Hietzing — Vienna,
LMC Clinical Research Inc. (Barrie) — Barrie,
LMC Clinical Research Inc. (Thornhill) — Concord,
Centre intégré universitaire de santé et de services sociaux de l'Estrie Centre Hospitalier Universitaire -T — Sherbrooke,
Toronto General Hospital — Toronto,
Fadia El Boreky Medicine — Waterloo,
Aarhus Universitetshospital, Skejby — Aarhus,
Centro de Investigación y Gastroenterología — Cuauhtémoc,
Investigación Nefrológica — Cuernavaca,
Health Pharma Professional Research S.A. de C.V: — Mexico City,
Grupo Medico Camino Sc — Mexico City,
Caimed Investigacion En Salud S.A. de C.V. — Mexico City,
Instituto Nacional de Cardiologia Ignacio Chavez — México,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Overweight

A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight — Tempe, Arizona
Community Park-Based Programs for Health Promotion: Fit2Play Prospective Cohort Study — Miami, Florida
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin — Birmingham, Alabama
Simplifying Diet Tracking in a Digital Weight Loss Intervention — Palo Alto, California
A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity — Tempe, Arizona

Explore by condition: All Overweight clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗